Literature DB >> 8352253

Atherogenic lipids and lipoproteins in hemodialysis patients.

A K Cheung1, L L Wu, C Kablitz, J K Leypoldt.   

Abstract

Dyslipidemia may contribute to atherosclerosis in hemodialysis patients. While hypertriglyceridemia is relatively common in this population, hypercholesterolemia is not. Since abnormalities in various plasma cholesterol fractions and lipoproteins have been associated with an increased incidence of cardiovascular disease in the nonuremic population, we examined these abnormalities to determine whether they occur in patients with chronic renal failure. Twenty-four patients on maintenance hemodialysis were studied. We found that, despite relatively low plasma total cholesterol levels, a substantial number of patients had low high-density lipoprotein cholesterol, low apolipoprotein AI, and high apolipoprotein B levels. Furthermore, approximately 40% and 30%, respectively, of the patients had elevated plasma levels of lipoprotein(a) and remnants of chylomicron and very low-density lipoprotein. Lipoprotein(a) levels could not be predicted from any of the variables that were studied. The abnormal plasma levels of these potentially atherogenic lipids and lipoproteins suggest that they may contribute to the high incidence of cardiovascular diseases in the hemodialysis population.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8352253     DOI: 10.1016/s0272-6386(12)70318-9

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

Review 1.  Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.

Authors:  Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2007-12-08       Impact factor: 2.370

2.  Accumulation of visceral fat in maintenance hemodialysis patients.

Authors:  Takatomi Yurugi; Satoshi Morimoto; Takayuki Okamoto; Yoshifumi Amari; Yuko Kasuno; Masayoshi Fukui; Fumitaka Nakajima; Mitsushige Nishikawa; Toshiji Iwasaka
Journal:  Clin Exp Nephrol       Date:  2011-10-13       Impact factor: 2.801

Review 3.  Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.

Authors:  Jacek Rysz; Anna Gluba-Brzózka; Maciej Banach; Andrzej Więcek
Journal:  Int Urol Nephrol       Date:  2015-03-11       Impact factor: 2.370

4.  Mechanism underlying an elevated serum bile acid level in chronic renal failure patients.

Authors:  Lei Chu; Kangkang Zhang; Yingying Zhang; Xunbo Jin; Huaxin Jiang
Journal:  Int Urol Nephrol       Date:  2014-12-25       Impact factor: 2.370

Review 5.  Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.

Authors:  Mona Khurana; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2015-03-24       Impact factor: 3.714

6.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

Review 7.  Statins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trials.

Authors:  Sankar D Navaneethan; Francesca Pansini; Giovanni F M Strippoli
Journal:  PLoS Med       Date:  2006-05-30       Impact factor: 11.069

8.  The lipid story in chronic kidney disease: a long story with a happy end?

Authors:  Agata Kujawa-Szewieczek; Andrzej Więcek; Grzegorz Piecha
Journal:  Int Urol Nephrol       Date:  2013-10       Impact factor: 2.370

9.  Oral L-glutamine rescues fructose-induced poor fetal outcome by preventing placental triglyceride and uric acid accumulation in Wistar rats.

Authors:  Kehinde Samuel Olaniyi; Isaiah Woru Sabinari; Lawrence Aderemi Olatunji
Journal:  Heliyon       Date:  2020-12-28

10.  Acetate rescues defective brain-adipose metabolic network in obese Wistar rats by modulation of peroxisome proliferator-activated receptor-γ.

Authors:  Kehinde Samuel Olaniyi; Morounkeji Nicole Owolabi; Chukwubueze Lucky Atuma; Toluwani Bosede Agunbiade; Bolanle Yemisi Alabi
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.